How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,678 results for

Cancer Survivor Care

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Management of Female Malignant Ovarian Germ Cell Tumours

treatment Women who have residual masses at completion of chemotherapy should be offered resection even if the tumour markers are normal. 41 This is to exclude residual disease or any residual mature teratoma which can progress as mature teratoma growing syndrome in up to 30% of cases, and more rarely, over time, undergo malignant transformation into an incurable tumour type, such as squamous carcinoma. Early recognition of this syndrome is essential as it offers hope for curative resection and avoids (...) for female malignant germ cell tumors. Obstet Gynecol 2006;107: 1075–85. 6. Arora RS, Alston RD, Eden TO, Geraci M, Birch JM. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. Cancer 2012;118:4290–7. 7. Talerman A. Germ cell tumours of the ovary. In: Kurman RJ, editor. Blaustein’s Pathology of the Female Genital Tract. New York: Springer Verlag; 1994. p. 849. 8. Tewari K, Cappuccini F , Disaia PJ, Berman ML, Manetta A, Kohler MF . Malignant

2016 Royal College of Obstetricians and Gynaecologists

2. Follow-up of Malignant or Aggressive Musculoskeletal Tumors

Follow-up of Malignant or Aggressive Musculoskeletal Tumors Date of origin: 1998 Last review date: 2015 ACR Appropriateness Criteria ® 1 Follow-up Musculoskeletal Tumors American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Follow-up of Malignant or Aggressive Musculoskeletal Tumors Variant 1: Lower-risk patient (low grade). Evaluation for metastatic disease to the lung from musculoskeletal primary. Baseline examination at time of diagnosis. Radiologic Procedure (...) Condition: Follow-up of Malignant or Aggressive Musculoskeletal Tumors Variant 3: Higher-risk patient (high grade). Evaluation for metastatic disease to the lung from musculoskeletal primary. Baseline examination at time of diagnosis. Radiologic Procedure Rating Comments RRL* CT chest without IV contrast 9 Despite some of the cost analysis studies, the panel believes early diagnosis of lung metastases is critical and that chest CT should be performed. If chest CT is done, chest x-ray is not necessary

2015 American College of Radiology

3. Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario

suggests that primary care is effective in promoting healthy lifestyle 35 (e.g., smoking cessation, 36,37 reduction of alcohol consumption). 38 Therefore, primary care is well-suited to lead prevention and health promotion activities for cancer survivors. 16. Regardless of who the MRP is (i.e., primary care provider or a specialist), primary care provider should be responsible for activities related to health promotion and prevention of disease. Primary care provider should work with the survivor (...) of time during which the cancer could not be detected. The cancer may come back to the same place as the original (primary) tumor or to another place in the body. 7 Re-referral The process in which a primary care provider refers a survivor back to the same specialist who has previously provided care. Supportive care A specialty in cancer care concerned with understanding and treating the social, psychological, emotional, spiritual, quality-of-life, and functional aspects of cancer, from prevention

2019 Cancer Care Ontario

4. Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000–2008 Full Text available with Trip Pro

Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000–2008 "Conditional survival probability" is defined as the probability that a patient will survive an additional time, given that the patient has already survived a defined period of time after diagnosis. Such estimates might be more relevant for clinicians and patients during post-diagnosis care, because survival probability projections are based on the patient's survival to date. Here, we provides the first (...) the study criteria, scs increased by a margin of 16-18 percentage points from 6-month survivors to 2-year survivors for the three most aggressive brain cancers. The lcs for 2-year survivors was 66% or greater for all tumour groups except glioblastoma. The lcs for 4-year survivors was 62% or greater for all histologies. For glioblastoma and diffuse astrocytoma, the lcs increased each year after diagnosis. For all other histologies, the lcs first increased and then plateaued from 2 years after diagnosis

2017 Current Oncology

5. Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Full Text available with Trip Pro

Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Subsequent malignant neoplasms (SMNs) are associated with significant morbidity and are a major cause of premature mortality among cancer survivors. Several large studies have demonstrated a strong association between the radiation and/or chemotherapy used to treat primary cancer and the risk of developing SMNs. However, for any given therapeutic exposure, the risk (...) of therapy-related SMNs, such as an appropriate study design, the identification of an adequately sized study population together with a reliable plan for collecting and maintaining high-quality DNA, clinical validation of the phenotype, and the selection of an appropriate approach or platform for genotyping. Understanding the factors that can modify the risk of treatment-related SMNs is critical to developing targeted intervention strategies and optimizing risk-based health care for cancer survivors

2014 Cancer

6. Resilience and quality of life (QoL) of head and neck cancer and brain tumour survivors in Pakistan: an analytical cross-sectional study protocol. Full Text available with Trip Pro

Resilience and quality of life (QoL) of head and neck cancer and brain tumour survivors in Pakistan: an analytical cross-sectional study protocol. Cancer is a devastating disease and has detrimental effects on the quality of life (QoL) of cancer survivors and interferes with their treatment compliance. The aim of the study is to assess resilience and QoL among cancer survivors and to evaluate the important factors affecting their resilience and QoL, with respect to the Pakistani cultural (...) context.A cross-sectional study will be conducted at a tertiary care hospital in Karachi, Pakistan. A minimum sample size of 250 head and neck cancers and 250 brain tumour survivors with 10% inflation for non-response rate will be required. The SD of QoL and resilience will range from 16.5 to 40.8 for head and neck cancer, and 12.7 to 34.1 for brain tumour, at 5% level of significance, with 2.5 precision. QoL will be assessed by European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30

2019 BMJ open

7. ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

patients present- ing with advanced stage tumours, as de?ned by the spread of the disease outside the pelvis [International Federation of Obstetrics and Gynaecology (FIGO) stage III and IV]. The estimated number of new ovarian cancer cases in Europe in 2012 was 65 538 with 42 704 deaths [1]. More than two-thirds of patients are diagnosed at an advanced stage. More than 90% of malignant ovarian tumours are of epithelial origin, designated epithelial ovarian cancer (EOC). The most common and most lethal (...) of high-risk patients within the ICON7 trial [22]. Although therapy targeting VEGF has become the standard of care in tubo-ovarian carcinomas as well as other solid malignancies, attempts to identify predictive molecular biomarkers for ef?cacy have failed to identify any that could help oncologists decide who should and, more importantly, who should not receive VEGF- targeted therapies, including bevacizumab [26]. Angiogenic markers, such as CD31 expression, microvessel density and tumour VEGF

2019 European Society for Medical Oncology

8. Cognitively-Based Compassion Training versus cancer health education to improve health-related quality of life in survivors of solid tumor cancers and their informal caregivers: study protocol for a randomized controlled pilot trial. Full Text available with Trip Pro

Cognitively-Based Compassion Training versus cancer health education to improve health-related quality of life in survivors of solid tumor cancers and their informal caregivers: study protocol for a randomized controlled pilot trial. Cancer survivors and their informal caregivers (family members, close friends) often experience significant impairments in health-related quality of life (HRQOL), including disruptions in psychological, physical, social, and spiritual well-being both during (...) in both cancer survivors and informal caregivers.Forty dyads consisting of solid tumor survivors who have completed primary treatments (chemotherapy, radiation, surgery) and their informal caregivers, with at least one dyad member with ≥ mild depressive symptoms or anxiety, will be recruited from Tucson, Arizona, USA. Survivor-caregiver dyads will be randomized together to complete either CBCT or CHE. CBCT is a manualized, 8-week, group meditation-based intervention that starts with attention

2019 Trials Controlled trial quality: uncertain

9. Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience

adding more. Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02557230 Recruitment Status : Recruiting First Posted : September 23, 2015 (...) Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2015 Clinical Trials

10. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer

and could be considered for inclusion in the evidence base. As a second stage, the focus was on locating and evaluating primary literature not already covered in any existing systematic reviews. PubMed was used to systematically search for articles evaluating the clinical utility of germline and somatic tumor testing in ovarian cancer, again between 2007 and March 23, 2018. The search combined disease-specific terms (neoplasm, carcinoma, cancer) along with site-specific terms (ovary, ovarian) and gene (...) pathogenic variants in BRCA1/2 genes should be offered treatments that are US Food and Drug Administration (FDA) approved in the upfront and the recurrent setting. Women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer should be offered somatic tumor testing for mismatch repair deficiency (dMMR). Women with identified dMMR should be offered FDA-approved treatment based on these results. Genetic evaluations should be conducted in conjunction with health care providers familiar

2020 American Society of Clinical Oncology Guidelines

11. Sequential Organ Failure Assessment Score Modified for Recent Infection in Patients With Hematologic Malignant Tumors and Severe Sepsis. Full Text available with Trip Pro

with hematologic malignant tumors and severe sepsis.©2016 American Association of Critical-Care Nurses. (...) Sequential Organ Failure Assessment Score Modified for Recent Infection in Patients With Hematologic Malignant Tumors and Severe Sepsis. Baseline health status influences outcomes of severe sepsis.To determine if recent infection is a marker of poor health in patients with hematologic malignant tumors and severe sepsis by modifying the Sequential Organ Failure Assessment (SOFA) score to account for infection.Medical records of the first 50 patients with hematologic malignant tumors and severe

2016 American Journal of Critical Care

12. Perspectives on Conversations About Costs of Cancer Care of Breast Cancer Survivors and Cancer Center Staff: A Qualitative Study. Full Text available with Trip Pro

Perspectives on Conversations About Costs of Cancer Care of Breast Cancer Survivors and Cancer Center Staff: A Qualitative Study. Despite recommendations to discuss the cost of care (CoC) with patients with cancer, little formal guidance is available on how to conduct these sensitive conversations in ways that are acceptable to both patients and providers.To explore the perspectives of patients and medical and nonmedical cancer center staff on CoC conversations.In individual interviews (...) be compassionate, helpful, and knowledgeable of the patient's specific situation (for example, treatment plan, insurance coverage) and of the resources available to attain the patient's goals of care.Interviews were limited to older breast cancer survivors and staff at 1 institution.Conversations about CoC extend beyond discussing costs and must be sensitive to the vulnerability experienced by patients. These findings can guide training of personnel involved in CoC conversations.Robert Wood Johnson Foundation.

2019 Annals of Internal Medicine

13. A Prospective, Observational, Real-world Study Based on the Register System of Oral and Maxillofacial Malignant Tumors

. Condition or disease Intervention/treatment Head and Neck Neoplasms Quality of Life Postoperative Complications Procedure: resection Radiation: adjuvant radiotherapy Drug: neoadjuvant chemotherapy or adjuvant chemotherapy Detailed Description: A register system of oral and maxillofacial malignant tumors based on a prospective, observational, real-world study in north Chinese population was absent. The aim of the study is to construct a register system of oral and maxillofacial malignant tumors based (...) [ Time Frame: 5 years ] Disease-specific survival was calculated as the time from the first operation to the time of death or last follow-up; patients who died from causes other than oral and maxillofacial cancer were defined as survivors at the time of death. Secondary Outcome Measures : tumor recurrence [ Time Frame: 5 years ] Tumor recurrence was defined as local recurrence postoperatively. neck recurrence [ Time Frame: 5 years ] Neck recurrence was defined as regional recurrence whether

2015 Clinical Trials

14. Pregnancy after malignancy in childhood: communication and information needs of female survivors and recommendations for optimal care

Pregnancy after malignancy in childhood: communication and information needs of female survivors and recommendations for optimal care Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler

2019 PROSPERO

15. Survivors of cancer seeking care continuity and lengthier appointments

Survivors of cancer seeking care continuity and lengthier appointments HEAL TH EC ONOMICS RESEARCH UNIT Promoting Excellence in Health Economics HERU is supported by the Chief Scientist Office (CSO) of the Scottish Government Health & Social Care Directorates (SGHSC) Survivors of cancer seeking care continuity and lengthier appointments policy brief March 2017 Key Findings • Cancer survivors may accept non-consultant follow-up as long as they receive other benefits. • Care continuity (...) was sufficient compensation in most types of cancer, along with longer appointments, one-to-one counselling and dietary advice. • Given practicalities, costs, and the potential to develop continuous care, specialist nurse-led cancer follow-up may be attractive. • Preferences differed between survivors of different cancers. What problem was this research addressing? After completing their primary treatment, most patients with cancer enter structured cancer follow-up aimed at detecting cancer recurrence

2017 Health Economics Research Unit

16. Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia

). Please remove one or more studies before adding more. Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03430752 (...) Recruitment Status : Recruiting First Posted : February 13, 2018 Last Update Posted : February 13, 2018 See Sponsor: The University of Hong Kong Information provided by (Responsible Party): The University of Hong Kong Study Details Study Description Go to Brief Summary: The aim of the study is to examine the impact of cancer and treatment-related effects on the physical and psychosocial well-being and quality of life among Hong Kong Chinese survivors of childhood solid tumors. Condition or disease

2018 Clinical Trials

17. Chinese translation of a measure of symptom burden, functional limitations, lifestyle, and health care-seeking skills in breast cancer survivors: the Cancer Survivor Profile. (Abstract)

Chinese translation of a measure of symptom burden, functional limitations, lifestyle, and health care-seeking skills in breast cancer survivors: the Cancer Survivor Profile. To produce a culturally sensitive Chinese translation of the original version of the Cancer Survivor Profile for breast cancer (CSPro-BC) survivors, which identifies problems in breast cancer patients post-primary treatment for breast cancer.Four hundred forty-four female Chinese patients following primary treatment (...) , lifestyle, and health care-seeking skills in Chinese-speaking breast cancer survivors is available for further testing.

2019 Journal of cancer survivorship : research and practice Controlled trial quality: uncertain

18. Alternating Electric Fields ("Tumour- Treating Fields") for the Treatment of Glioblastoma

more slowly from a lower-grade glioma, usually occurs in younger patients. 31 Precise numbers of Canadians with glioblastoma are not available, but based on estimates of the incidence of the disease from the US and Europe, approximately 1,200 Canadians may be diagnosed with glioblastoma each year. 5,9,31 The Brain Tumour Foundation of Canada’s Canadian Brain Tumour Registry is collecting information on the incidence and survival rates for all types of brain cancers, and more comprehensive data (...) , and ovarian cancers. 8,11,13,17,36 A Danish trial is investigating the feasibility of increasing TTField intensity to the tumour by craniectomy ― removing small pieces of the overlaying skull.52 A report of compassionate use of TTFields treatment in five children and adolescents with high grade gliomas (including glioblastoma) concluded a pediatric trial would be worthwhile, 90 and the Pediatric Brain Tumor Consortium is conducting a trial in children. 91 Implementation Issues Uptake A 2017 US review

2018 CADTH - Issues in Emerging Health Technologies

19. Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline

clinical, planning, and policy decisions about cancer control. The PEBC is a provincial initiative of CCO supported by the Ontario Ministry of Health and Long-Term Care (OMHLTC). All work produced by the PEBC is editorially independent from the OMHLTC. BACKGROUND FOR GUIDELINE There were originally three guidelines, divided into chemotherapy, surgical, and radiation therapy topics, that covered the treatment of patients with malignant pleural mesothelioma. The CCO Lung Cancer Disease Site Group (DSG (...) Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline Guideline Endorsement 7-14 Version 3 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline M. de Perrot, E.T. Vella, P. Bradbury, J. Cho, C. Dennie, J. Goffin, R. MacRae, D. Maziak, M. Tsao, Y.C. Ung, P.M. Ellis, and the Lung

2018 Cancer Care Ontario

20. Complementary Therapy for Cancer Survivors: Integrative Nursing Care. Full Text available with Trip Pro

Complementary Therapy for Cancer Survivors: Integrative Nursing Care. The number of cancer patients who survive more than 5 years after the completion of their initial treatment is increasing. Oncology nurses must consider the needs of long-term cancer survivors in addition to those of cancer patients undergoing treatment because cancer survivors experience anxiety over several issues, including the risk of recurrence and progression of cancer status and symptom management.We tried to examine (...) with cancer because the majority of the patients were women. Meanwhile, the result suggests that CTs might be useful for long-term cancer survivors who experience anxiety that influence their quality of life.

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>